OrbiMed Advisors FOLD Position
Exited6-Fund ConvergenceOrbiMed Advisors exited their position in Amicus Therapeutics Inc. (FOLD) in Q3 2023, after holding the stock for 3 quarters.
The position was first reported in Q1 2023 and has been tracked across 3 quarterly 13F filings.
FOLD is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Cipaglucosidase Alfa in 75 days (Jun 30, 2026), making the timing of OrbiMed's position particularly relevant.
About Amicus Therapeutics Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Full company profile →Short Interest
6.5%
5.5 days to cover
OrbiMed Advisors FOLD Position History
Frequently Asked Questions
Does OrbiMed Advisors own FOLD?
No. OrbiMed Advisors exited their position in Amicus Therapeutics Inc. (FOLD) in Q3 2023. They previously held the stock for 3 quarters.
How many hedge funds own FOLD?
6 specialist biotech hedge funds currently hold FOLD, including Perceptive Advisors, Avoro Capital Advisors, Redmile Group and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy FOLD?
OrbiMed Advisors's position in FOLD was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's FOLD position increasing or decreasing?
OrbiMed Advisors completely exited their FOLD position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
FOLDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →